AnaptysBio (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:60Neutral
Price Target:
$57.00
▼(-15.57% Downside)
Action:Reiterated
Date:05/14/26
The score is driven by strong technical strength (clear uptrend with supportive momentum) but capped by mixed fundamentals—improving operations and cash generation offset by volatile TTM results and a weakened balance sheet. Valuation also weighs on the score due to continued net losses (negative P/E), while recent corporate actions are a moderate positive tailwind.
Positive Factors
Royalty-focused business model
The April 2026 spin-off refocused AnaptysBio as a royalty manager, keeping Jemperli and imsidolimab royalties and collaborations. A royalty-centric model lowers recurring R&D burn, stabilizes cash inflows tied to partner commercialization, and supports a lower-cost virtual operating structure over the medium term.
Negative Factors
Deteriorated balance sheet leverage
Equity declined and leverage rose above 1x in the trailing twelve months, reducing the balance sheet cushion. Higher leverage limits financial flexibility, raises refinancing and covenant risk, and increases sensitivity to irregular royalty or milestone receipts over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Royalty-focused business model
The April 2026 spin-off refocused AnaptysBio as a royalty manager, keeping Jemperli and imsidolimab royalties and collaborations. A royalty-centric model lowers recurring R&D burn, stabilizes cash inflows tied to partner commercialization, and supports a lower-cost virtual operating structure over the medium term.
Read all positive factors
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.63B
Dividend YieldN/A
Average Volume (3M)582.68K
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth107.73%
EPS Growth82.33%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,100,903
10 Day Avg. Volume564,507
30 Day Avg. Volume582,684
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue10.45
Enterprise Value/Gross Profit8.98
Enterprise Value/Ebitda41.54
Forecast
1Y Price Target
$79.86Price Target Upside18.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$121.64M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc. is a biotechnology firm currently in the clinical development phase, dedicated to pioneering novel therapeutic agents aimed at treating inflammatory conditions and immuno-oncological diseases. The company's portfolio features seve...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (it is a clinical-stage company and does not consistently generate revenue from commercialized products). Key revenue streams typically inc...
AnaptysBio Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
45
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 232.39M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 270.54M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 58.49M | 69.25M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -26.79M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 329.68M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 286.45M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 277.36M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 316.94M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 12.75M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 4.41M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 4.48M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 248.17M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -102.81M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Positive
67.51
Price Trends
55.86
Positive
46.51
Positive
35.16
Positive
Market Momentum
-1.42
Positive
51.61
Neutral
67.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 67.51 is above the 20-day moving average (MA) of 55.65, above the 50-day MA of 55.86, and above the 200-day MA of 35.16, indicating a bullish trend. The MACD of -1.42 indicates Positive momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 67.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.63B | -60.06 | 442.91% | ― | 107.73% | 82.33% | |
56 Neutral | $888.13M | -6.47 | 474.91% | ― | 131.13% | 35.61% | |
53 Neutral | $200.89M | -4.44 | -17.04% | ― | -84.55% | -1998.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $365.58M | -5.55 | -39.75% | ― | -100.00% | -2.72% | |
46 Neutral | $862.12M | -5.48 | -45.95% | ― | ― | -3.83% |
* Healthcare Sector Average
ANAB
AnaptysBio
56.07
40.14
251.98%
MGTX
Meiragtx Holdings
9.59
2.97
44.86%
KROS
Keros Therapeutics
10.15
-3.51
-25.70%
CMPX
Compass Therapeutics
2.03
-0.34
-14.35%
OLMA
Olema Pharmaceuticals
9.87
5.68
135.56%
AnaptysBio Corporate Events
DividendsRegulatory Filings and Compliance
AnaptysBio Details Tax Treatment of Spin-Off Dividend
Neutral
May 29, 2026
AnaptysBio, Inc. has filed IRS Form 8937 and plans to make the related information available on its website to explain the dividend received by stockholders from the separation and spin-off of First Tracks Biotherapeutics, Inc. The filing outlines...
Business Operations and StrategyRegulatory Filings and Compliance
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
Neutral
May 21, 2026
On May 18, 2026, AnaptysBio, Inc.’s board of directors approved a shift in the company’s fiscal year-end from December 31 to June 30, with the next fiscal year set to begin on July 1, 2026. The company will file a transition Form 10-KT...
Executive/Board Changes
AnaptysBio Appoints New CFO and Board Director
Positive
May 11, 2026
On May 11, 2026, AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer, formalizing his role through a consulting agreement that designates him as an independent contractor with performance-based compensation and a $1.75 mill...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
Positive
Apr 20, 2026
On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, separating its biotechnology RD operations from a royalty-focused business that will retain and manage Jemperli and imsidolimab royalty streams and related colla...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
Positive
Mar 27, 2026
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.